ACI
EDIT icon

AMP Capital Investors’s Editas Medicine EDIT Stock Holding History

AMP Capital Investors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,300
Closed -$336K – 1180
2018
Q1 		$336K Buy
+10,300
New +$367K ﹤0.01% 1058

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AMP Capital Investors's EDIT Position: Q2 2018 in Review

AMP Capital Investors sold out of Editas Medicine (EDIT) in Q2 2018, closing a stake of 10,300 shares — an estimated $336K sold.

AMP Capital Investors first reported a position in EDIT in Q1 2018 and held it in 1 quarter. The position peaked at $336K in Q1 2018. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2018.

  • AMP Capital Investors reported no remaining Editas Medicine position as of Q2 2018 after selling out during the quarter.
  • AMP Capital Investors sold 10,300 Editas Medicine shares in Q2 2018, an estimated $336K.
  • AMP Capital Investors first reported a position in Editas Medicine in Q1 2018 and held it in 1 quarter.
  • AMP Capital Investors's Editas Medicine position peaked at $336K in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2018.

Based on AMP Capital Investors's 13F filing for Q2 2018, filed 13 Aug 2018.